drugset
drugset / Trial / NCT02170402

China ADVATE PTP Study

NCT02170402 ↗

Phase 4 Completed 82 enrolled Baxalta now part of Shire
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess efficacy, safety and pharmacokinetics of ADVATE in the treatment and prevention of bleeding episodes (BEs)

Timeline

Start
2014-06-26
Primary completion
2016-05-31
Completion
2016-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic — —

Indications

hemophilia A